Pelvic Floor Yoga Not Superior for Women With Urinary Incontinence
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 26, 2024 -- A 12-week pelvic floor yoga program is not superior to a physical conditioning program for women with daily urinary incontinence, according to a study published online Aug. 27 in the Annals of Internal Medicine.
Alison J. Huang, M.D., from the University of California San Francisco, and colleagues examined the effects of a therapeutic pelvic floor yoga program versus a nonspecific physical conditioning program on UI among ambulatory women aged 45 years or older in a study conducted at three sites in California. The intervention consisted of a 12-week program of pelvic floor-specific Hatha yoga techniques (pelvic yoga) versus equivalent-time instruction and practice of general muscle stretching and strengthening (physical conditioning).
Of the 240 women reporting daily urgency-, stress-, or mixed type-UI, the mean baseline UI frequency was 3.4 episodes per day, including 1.9 and 1.4 urgency-type and stress-type episodes, respectively, per day. The researchers found that total UI frequency decreased by an average of 2.3 and 1.9 episodes per day during a 12-week time period with pelvic yoga and physical conditioning, respectively. There was a per-day decrease of 1.2 and 1.0 episodes of urgency-type UI in the pelvic yoga and physical conditioning groups, respectively. No difference was seen in the reductions in stress-type UI frequency between the groups.
"As a pleiotropic behavioral intervention, yoga may offer greater therapeutic benefit for urgency UI as an inherently more complex syndrome," the authors write. "However, changes in type-specific UI were secondary outcomes only and require more investigation."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-27 09:15
Read more
- Iowa Resident Dies of Suspected Lassa Fever After Trip to West Africa
- FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
- Prepping for Colonoscopy? An Expert Offers Tips to Make Things Easier
- 3 Years of Med School Might Be Enough to Produce Quality Doctors
- USPSTF Recommends Providing Interventions to Support Breastfeeding
- Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions